Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Estrogen receptor alpha (ERalpha) plays an important role in breast cancer. Upregulation of HIF-1alpha in ER(alpha)-positive cancers suggests that HIF-1alpha may cooperate with ERalpha to promote breast cancer progression and consequently affect breast cancer treatment. Here, we show the histone demethylase JMJD2B is regulated by both ERalpha and HIF-1alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes such as CCND1, CCNA1, and WEE1. We also show that JMJD2B and the hypoxia marker CA9 together stratify a subclass of breast cancer patients and predict a worse outcome of these breast cancers. Our findings provide a biological rationale to support the therapeutic targeting of histone demethylases in breast cancer patients.

Original publication

DOI

10.1158/0008-5472.CAN-10-0413

Type

Journal article

Journal

Cancer res

Publication Date

15/08/2010

Volume

70

Pages

6456 - 6466

Keywords

Breast Neoplasms, Cell Cycle, Cell Growth Processes, Cell Hypoxia, Cell Line, Tumor, Epigenesis, Genetic, Estradiol, Estrogen Receptor alpha, Female, Genes, cdc, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Jumonji Domain-Containing Histone Demethylases, Signal Transduction